# US 2025/0367308 A1 · Ligand-drug conjugate of camptothecin analogs, intermediates, preparation method therefor, pharmaceutical composition and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367308 A1
- Document ID: US20250367308A1
- Status: Published application
- Kind: A1
- Application number: 18/861,184
- Filed: 2023-04-21
- Published: 2025-12-04
- Earliest claimed: 2022-04-29
- Assignees: Shanghai Micurx Pharmaceutical Co., Ltd.
- Applicants: Shanghai Micurx Pharmaceutical Co.,Ltd.
- Inventors: Hongyu YANG; Xinghai WANG
- Web page: https://patentgrep.com/patent/US20250367308A1

## CPC

- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61P 35/00: Antineoplastic agents
- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07K 16/32: against translation products of oncogenes
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are conjugates of novel camptothecin analogs with a cell binding molecule of formula (I). It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of application the conjugates in targeted treating of cancer.

## Claims

### Claim 1

A ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, wherein the ligand-drug conjugate comprises a structure of formula (IIa)
wherein:
Y and Z are independently selected from H halo, C1-C8 alkyl, and C1-C8 alkoxy;
R3 is selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
is

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 1, being a ligand-drug conjugate of formula (IIIa) or a pharmaceutically acceptable salt or solvate thereof:
wherein:
R1 and R2 are each hydrogen;
T is a targeting or binding ligand;
L is a releasable linker; and
m is an integer or fraction of integer selected from 1 to 10.

### Claim 4 (depends on 1)

The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein:
is

### Claim 5 (depends on 3)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 3, wherein m is an integer or fraction of an integer selected from 2 to 8; optionally m is an integer or fraction of an integer selected from 3 to 8.

### Claim 6 (depends on 3)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 3, wherein L is -L1-L2-L3-L4-, and optionally wherein L1 is connected to the ligand, and the L4 is connected to X2 and X2 is —O—;
L1 is selected from the group consisting of
—CH2—C(O)—NR10—W—C(O)—, C(O)—W—C(O)—, and —W—, wherein W and W1 are independently selected from the group consisting of C1-C8 alkylene, —(C1-C8 alkylene)-cycloalkylene-, arylene, heteroarylene, and linear heteroalkylene, wherein the linear heteroalkylene comprise 1 to 8 carbon atom(s), and 1 to 3 heteroatom(s) selected from the group consisting of N, O, S, SO, and SO2, and wherein the —(C1-C8 alkylene)-cycloalkylene-, linear heteroalkylene, arylene, and heteroarylene are each independently optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the left side of each of the L1 groups provided above is attached to T;
L2 is selected from the group consisting of —NR11(CH2CH2O)p1CH2CH2C(O)—, —NR11(CH2CH2O)p1CH2CH2—, —NR11(CH2CH2O)p1CH2C(O)—, —S(CH2)p1C(O)—, and a chemical bond, wherein p1 at each occurrence is an integer selected from 1 to 20; and L2 is preferably a chemical bond; wherein the left side of each of the L2 groups provided above is attached to L1;
L3 is a peptide residue composed of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the left side of each of the L3 groups provided above is attached to L2;
L4 is selected from the group consisting of —NR12(CR13R14)—, —C(O)NR12—, —C(O)NR12(CH)t—,
and a chemical bond, wherein t at each occurrence is an integer selected from 1 to 6; and L4 is preferably —NR12(CR13R14)t−; wherein the left side of each of the L4 groups provided above is attached to the right side of L3 and the right side of each of the L4 groups is attached to X2;
R10, R11 and R12 are each independently selected from the group consisting of H, allyl, haloalkyl, deuterated alkyl and hydroxyalkyl;
R13 and R14 are each independently selected from the group consisting of H, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and
R15 is selected from —CH2CH2SO2CH3, and —CH2CH2N(CH3)2
optionally wherein L1 is selected from the group consisting of
—CH2—C(O)—NR10—(CH2)s3-C(O)— (wherein the left hand side of this group is attached to T), —C(O)—(CH2)s4-C(O)— (wherein the left hand side of this group is attached to T), and —C6H4—, wherein s1 is an integer selected from 2 to 8; s2 is an integer selected from 1 to 3; s3 is an integer selected from 1 to 8; and s4 is an integer selected from 1 to 8; and/or
optionally wherein L2 is selected from the group consisting of —NR11(CH2CH2O)p1CH2CH2C(O)—, —NR11(CH2CH2O)p1CH2CH2—, —NR11(CH2CH2O)p1CH2C(O)—, —S(CH2)p1C(O)—, and a chemical bond, wherein p1 is an integer selected from 6 to 12; and/or
optionally L3 is a peptide residue composed of 2 to 7 amino acids, wherein the amino acids are selected from Phenylalanine (F), Glycine (G), Valine (V), Lysine (K), Citrulline, Serine (S), Glutamic acid (E), and Aspartic acid (N); preferably a peptide residue composed of 1, 2 or more Phenylalanine and Glycine; more preferably is a peptide residue composed of 4 amino acids; the most preferably is a peptide residue composed of GGFG; and/or
optionally L4 is —NR12(CR13R14)t-, R12 is H or alkyl, R13 and R14 are each independently selected from H and alkyl, t is 1 or 2; L4 is optionally —NR12CR13R14—; L4 is preferably —NHCH2—.

### Claim 7 (depends on 3)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 3, wherein L is -L1-L2-L3-L4-,
L1 is
L2 is a chemical bond;
L3 is a peptide residue comprising 4 amino acids;
L4 is —NR12(CR13R14)t-, R12 is H or alkyl, R13 and R14 are each independently H or alkyl, and
t is 1 or 2.

### Claim 8 (depends on 3)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 3, wherein L is -L1-L2-L3-L4-,
L1 is
L2 is —NR11(CH2CH2O)9CH2CH2C(O)—;
L3 is a peptide residue comprising 4 amino acids;
L4 is —NR12(CR13R14)t-, R12 is H or alkyl, R13 and R14 are each independently H or alkyl, and
t is 1 or 2.

### Claim 9 (depends on 1)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 1, selected from:

### Claim 10 (depends on 3)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 3, wherein the ligand-drug conjugate is according to formula (IIIa), or a pharmaceutically acceptable salt or solvate thereof:
wherein T is a targeting antibody or ligand binding to antigen; wherein the antibody is selected from chimeric antibody, humanized antibody and human antibody; and optionally wherein T is a monoclonal antibody; or
wherein T is selected from anti-Her2(ErbB2) antibody, anti-EGFR antibody, anti-B7H3 antibody, anti-c-MET antibody, anti-Her3(ErbB3) antibody, anti-Her4(ErbB4) antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MICI antibody, anti-Lewis Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody or anti-Mesothelin antibody, and anti-ROR1 antibody or the fragment binding to the antigen; or
wherein T is selected from Trastuzumab, Pertuzumab, Nimotuzumab, Enoblituzumab, Emibetuzumab, Inotuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96 and Glembatumumab or the fragment binding to the antigen.

### Claim 11 (depends on 1)

The ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to claim 1, selected from:

### Claim 12

A compound of formula (Va), or a pharmaceutically acceptable salt or solvate thereof:
wherein:
Y and Z are independently selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
R3 is selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
is
R1 and R2 are each hydrogen;
n3 is 1;
W is selected from the group consisting of C1-C8 alkylene, —(C1-C8 alkylene)-cycloalkylene-, arylene, heteroarylene, and linear heteroalkylene, wherein the linear heteroalkylene comprise 1 to 8 carbon atom(s), and 1 to 3 heteroatom(s) selected from the group consisting of N, O, S, SO, and SO2, and wherein the —(C1-C8 alkylene)-cycloalkylene-linear heteroalkylene, arylene, and heteroarylene are each independently optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
L2 is the group consisting of —NR11(CH2CH2O)p1CH2CH2C(O)—, —NR11(CH2CH2O)p1CH2CH2—, —NR11(CH2CH2O)p1CH2C(O)—, —S(CH2)p1C(O)— and a chemical bond, wherein p1 is an integer selected from 1 to 20; wherein the left side of each of the L2 groups provided above is attached to L1;
L3 is a peptide residue composed of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl; wherein the left side of each of the L3 groups provided above is attached to L2;
L4 is selected from the group consisting of —NR12(CR13R14)t-, —C(O)NR12—, —C(O)NR12(CH)t—,
and a chemical bond, wherein t is an integer selected from 1 to 6; wherein the left side of each of the L4 groups provided above is attached to the right side of L3 and the right side of each of the L4 groups is attached to X2;
R10, R11 and R12 are each independently selected from the group consisting of H, allyl, haloalkyl, deuterated alkyl and hydroxyalkyl;
R13 and R14 are each independently selected from the group consisting of H, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl; and
R15 is selected from —CH2CH2SO2CH3, and —CH2CH2N(CH3)2.

### Claim 13 (depends on 12)

The compound of claim 12, selected from structures below:

### Claim 14

A compound of formula (VIIa) or a pharmaceutically acceptable salt thereof:
wherein:
Y and Z are independently selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
R3 is selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
is

### Claim 15 (depends on 14)

The compound according to claim 14, wherein:
is

### Claim 16 (depends on 14)

The compound according to claim 14, selected from structures below:

### Claim 17 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of the ligand-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof, according to claim 1, and pharmaceutically acceptable carrier(s), diluent(s), or excipient(s).

### Claim 18 (depends on 1)

A method of treating cancer, the method comprising administering to a subject in need thereof a ligand-drug conjugate, or the pharmaceutically acceptable salt or solvate thereof, according to claim 1 wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, and lymphoma.

### Claim 19 (depends on 14)

A pharmaceutical composition, comprising a therapeutically effective amount of the compound, or the pharmaceutically acceptable salt or solvate thereof, according to claim 14, and pharmaceutically acceptable carrier(s), diluent(s), or excipient(s).

### Claim 20 (depends on 14)

A method of treating cancer, the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 14; wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, and lymphoma.

### Claim 21 (depends on 17)

A method of treating cancer, the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 17; wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, and lymphoma.

### Claim 22 (depends on 19)

A method of treating cancer, the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 19; wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, colorectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, and lymphoma.
